Kalaris Therapeutics (KLRS) Total Assets by Year
Kalaris Therapeutics, Inc. closed fiscal year 2025 with $121.7M in total assets, $42.9M in total liabilities and $78.8M in shareholder equity. Total assets rose 1875.6% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Kalaris Therapeutics, Inc. has filed alongside them.
Ticker history: ALVR became KLRS (Kalaris Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View ALVR history.
Annual figures, oldest first. Point at a bar to read its period.
KLRS Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K |
|---|---|---|---|---|---|---|---|
| Total Assets | $121.7M+1875.6% | $6.2M-96.8% | $190.8M-31.1% | $277.1M-3.3% | $286.6M-22.7% | $370.8M+166.0% | $139.4M |
| Total Liabilities | $42.9M-58.2% | $102.8M-56.4% | $235.8M+348.7% | $52.6M-14.3% | $61.3M+245.4% | $17.8M-90.7% | $190.9M |
| Total Equity | $78.8Mn/m | -$96.6Mn/m | -$45.0M-120.1% | $224.5M-0.3% | $225.3M-36.2% | $353.1Mn/m | -$51.5M |
KLRS Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $99.5M+7.2% | $109.8M+6.5% | $121.7M+1875.6% | $81.2M-33.8% | $92.8M-29.1% | $103.1M-28.5% | $6.2M-96.8% | $122.5M-50.7% | $131.0M-53.7% | $144.1M-40.9% | $190.8M-31.1% | $248.3M-15.5% |
| Total Liabilities | $41.9M+5.4% | $41.2M+5.2% | $42.9M-58.2% | $39.3M-81.4% | $39.7M-78.2% | $39.2M-79.5% | $102.8M-56.4% | $211.9M+300.0% | $182.5M+240.6% | $191.7M+279.5% | $235.8M+348.7% | $53.0M+30.9% |
| Total Equity | $57.7M+8.6% | $68.6M+7.3% | $78.8Mn/m | $41.9Mn/m | $53.1Mn/m | $63.9Mn/m | -$96.6Mn/m | -$89.4M-145.8% | -$51.5M-122.5% | -$47.5M-124.6% | -$45.0M-120.1% | $195.3M-22.9% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Kalaris Therapeutics, Inc. financials
Frequently Asked Questions
Kalaris Therapeutics, Inc. closed fiscal year 2025 with $121.7M in total assets, $42.9M in total liabilities and $78.8M in shareholder equity.
Kalaris Therapeutics, Inc. (KLRS) total assets rose by 1875.6% year over year, from $6.2M to $121.7M in fiscal year 2025.
Across the 7 fiscal years this page covers, Kalaris Therapeutics, Inc. (KLRS) total assets went from $139.4M in fiscal year 2019 to $121.7M in fiscal year 2025.
Kalaris Therapeutics, Inc. (KLRS) reported $99.5M in total assets in Q2 2026. This represents an increase of 7.2% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Kalaris Therapeutics, Inc. (KLRS) reported on that line in every period on record.